MALVERN, Pa., Nov. 15, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI ) announced today that it has entered into a definitive agreement with MC2 Therapeutics ("MC2") to commercialize Wynzora® Cream ...

Endo, Inc. (OTCQX: NDOI) announced today that it has entered into a definitive agreement with MC2 Therapeutics ("MC2") to commercialize Wynzora® Cream ...

Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.

A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis,” published in the November 2024 issue of Dermatology by Ferris et al.

One woman’s journey from receiving her diagnosis to finding a treatment that helps manage her chronic skin condition.

Organon is a strong investment opportunity with a high yield, diversified portfolio, steady performance, and transformative ...

Discover my top 27 lotions that I’ve personally used and loved for combating extremely dry skin. From hydrating formulas to ...

University of Copenhagen researchers have developed a prototype patch for treating plaque psoriasis, which may simplify ...

"The doctors were useless, just prescribing creams that weren't working ... When Emmy started the new medication she found ...

Researchers at the University of Massachusetts Amherst have invented a new, sprayable delivery system for psoriasis ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...